BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) infections are treated with pegylated interferon and ribavirin (PEG-IFN/RBV), which is effective in less than 50% of those infected with HCV genotype 1. Genome-wide association studies have linked response to PEG-IFN/RBV with common single nucleotide polymorphisms in the vicinity of interferon (IFN)-lambda genes on chromosome 19. We investigated the association between the polymorphism rs12979860 and treatment response in a diverse cohort of chronic HCV patients. METHODS: A cross-sectional study of 1021 consecutive patients enrolled in the Duke Hepatology Clinic Research Database and Biorepository. We analyzed DNA, clinical and demographic data, along with validated data of the response of 231 subjects to PEG-IFN/RBV. The study included Caucasians (n = 178), African Americans (n = 53), and HCV genotypes 1 (n = 186) and 2/3 (n = 45). The rs12979860 genotype was tested for an association with sustained virologic response, defined as undetectable levels of HCV RNA 24 weeks after treatment ended. RESULTS: The rs12979860 CC genotype (found in approximately 40% of Caucasians) predicted a sustained virologic response to therapy among Caucasians (odds ratio, 5.79; 95% confidence interval, 2.67-12.57; P = 9.0 x 10(-6)), independent of HCV genotype and other covariates. Rs12979860 CC predicted a sustained response with 78% specificity and 65% sensitivity in patients infected with HCV genotype 1). CONCLUSIONS: rs12979860 genotype is a significant independent predictor of response to PEG-IFN/RBV in patients with chronic HCV infection; tests for this genotype might be used to determine the best course of treatment for patients considering antiviral therapy. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
BACKGROUND & AIMS:Patients with chronic hepatitis C virus (HCV) infections are treated with pegylated interferon and ribavirin (PEG-IFN/RBV), which is effective in less than 50% of those infected with HCV genotype 1. Genome-wide association studies have linked response to PEG-IFN/RBV with common single nucleotide polymorphisms in the vicinity of interferon (IFN)-lambda genes on chromosome 19. We investigated the association between the polymorphism rs12979860 and treatment response in a diverse cohort of chronic HCVpatients. METHODS: A cross-sectional study of 1021 consecutive patients enrolled in the Duke Hepatology Clinic Research Database and Biorepository. We analyzed DNA, clinical and demographic data, along with validated data of the response of 231 subjects to PEG-IFN/RBV. The study included Caucasians (n = 178), African Americans (n = 53), and HCV genotypes 1 (n = 186) and 2/3 (n = 45). The rs12979860 genotype was tested for an association with sustained virologic response, defined as undetectable levels of HCV RNA 24 weeks after treatment ended. RESULTS: The rs12979860 CC genotype (found in approximately 40% of Caucasians) predicted a sustained virologic response to therapy among Caucasians (odds ratio, 5.79; 95% confidence interval, 2.67-12.57; P = 9.0 x 10(-6)), independent of HCV genotype and other covariates. Rs12979860 CC predicted a sustained response with 78% specificity and 65% sensitivity in patients infected with HCV genotype 1). CONCLUSIONS:rs12979860 genotype is a significant independent predictor of response to PEG-IFN/RBV in patients with chronic HCV infection; tests for this genotype might be used to determine the best course of treatment for patients considering antiviral therapy. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Authors: M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis Journal: N Engl J Med Date: 1999-08-19 Impact factor: 91.245
Authors: Gregory L Armstrong; Annemarie Wasley; Edgar P Simard; Geraldine M McQuillan; Wendi L Kuhnert; Miriam J Alter Journal: Ann Intern Med Date: 2006-05-16 Impact factor: 25.391
Authors: Tobias Marcello; Arash Grakoui; Giovanna Barba-Spaeth; Erica S Machlin; Sergei V Kotenko; Margaret R MacDonald; Charles M Rice Journal: Gastroenterology Date: 2006-10-01 Impact factor: 22.682
Authors: Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein Journal: Nature Date: 2009-08-16 Impact factor: 49.962
Authors: Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George Journal: Nat Genet Date: 2009-09-13 Impact factor: 38.330
Authors: Ian R White; Keyur Patel; William T Symonds; Anouk Dev; Philip Griffin; Nikos Tsokanas; Mark Skehel; Chiang Liu; Amany Zekry; Paul Cutler; Mahanandeeshwar Gattu; Don C Rockey; Michelle M Berrey; John G McHutchison Journal: J Transl Med Date: 2007-07-11 Impact factor: 5.531
Authors: L Nosotti; A Petrelli; D Genovese; S Catone; C Argentini; S Vella; A Rossi; G Costanzo; A Fortino; L Chessa; L Miglioresi; C Mirisola Journal: J Immigr Minor Health Date: 2017-08
Authors: Jessica D Tenenbaum; Victoria Christian; Melissa A Cornish; Rowena J Dolor; Ashley A Dunham; Geoffrey S Ginsburg; Virginia B Kraus; John G McHutchison; Meredith L Nahm; L Kristin Newby; Laura P Svetkey; Krishna Udayakumar; Robert M Califf Journal: Am J Transl Res Date: 2012-07-23 Impact factor: 4.060
Authors: A J Muir; L Gong; S G Johnson; M T M Lee; M S Williams; T E Klein; K E Caudle; D R Nelson Journal: Clin Pharmacol Ther Date: 2013-10-04 Impact factor: 6.875
Authors: Nikolaos K Gatselis; Kalliopi Zachou; Asterios Saitis; Maria Samara; George N Dalekos Journal: World J Gastroenterol Date: 2014-03-21 Impact factor: 5.742